PRAX-562 is under clinical development by Praxis Precision Medicines and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRAX-562’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRAX-562 overview

PRAX-562 is under development for the treatment of trigeminal neuralgia, short-lasting unilateral neuralgiform headache with autonomic symptoms (SUNA), SCN2A epilepsy, SCN8A epilepsy, tuberous sclerosis complex (TSC), short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and pain disorders. It is administered through oral route as capsule. It acts by targeting sodium channel protein type 8 subunit alpha (Nav1.6).

It was also under development for the treatment of epileptic encephalopathy (SCN2A-DEE and SCN8A-DEE).

Praxis Precision Medicines overview

Praxis Precision Medicines (Praxis), formerly EpiPM Therapeutics Inc, is a clinical statge biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050, PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders, It provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis incorporates large-scale genome sequencing and a neurocircuit biology-based approach to advance its pipeline products. The company’s funding partners include Vida ventures, Novo Holdings, Blackstone life sciences, and others. Praxis is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of PRAX-562’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.